PITTSBURGH, July 19 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today reported that the U.S. District Court for the District of New Jersey issued an opinion today which concluded that the relevant patent "may be properly construed to expressly claim topiramate". The final pretrial conference in this litigation is scheduled for September 19, with trial to be scheduled thereafter. At trial, Mylan will present its claims that the patent is invalid based on obviousness and is unenforceable due to Ortho-McNeil's inequitable conduct. Mylan will also continue to advocate its non- infringement defense. In April, 2005, the District Court judge granted Mylan's motion to dismiss Ortho's claims of willful infringement.

Forward-Looking Statements

This press release includes statements that constitute "forward-looking statements," including with regard to the Company's pending litigation. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: risks inherent in legal proceedings; other uncertainties and matters beyond the control of management; and the other risk factors set forth in the Company's Form 10-K for the year ended March 31, 2005, and in its other filings with the SEC. The Company undertakes no obligation to update statements herein for revisions or changes after the date of this release.

Mylan Laboratories Inc. is a leading pharmaceutical company with three subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., and UDL Laboratories, Inc., that develop, manufacture and market an extensive line of generic and proprietary products. For more information about Mylan, visit www.mylan.com.

SOURCE Mylan Laboratories Inc.
07/19/2005
CONTACT: Patrick Fitzgerald, Public Relations, or Kris King, Investor
Relations of Mylan Laboratories Inc., +1-724-514-1800
Web site: http://www.mylan.com
(MYL)